Saturday 17 October 2026
Export PBLA’s income statement to Excel — free account
Panbela Therapeutics Inc.
PBLA Healthcare Biotechnology
0.00
0.00
NaN
Follow PBLA
| Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.25 | 0.23 | 4.62 | 7.15 | 1.76 | 1.13 | 0.18 | 0.16 |
Net Debt/EBITDA |
(0.10) | (0.14) | 1.19 | 1.57 | 1.04 | 0.00 | (0.28) | (0.55) |
Debt/Assets |
44.01% | 124.43% | 0.00% | 0.00% | 3.69% | 18.44% | 0.00% | 373.66% |
Debt/Equity |
(1.10) | (0.77) | 0.00 | 0.00 | 0.08 | 1.31 | (0.49) | (0.71) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.00 | 0.44 | 0.71 | 0.81 | 0.44 | 0.40 | 0.33 | 0.47 |
Capex/Depreciation |
0.00 | 0.00 | — | — | 0.00 | — | — | — |
Interest Coverage |
(80.91) | (118.38) | (834.17) | (338.47) | (1.97) | (4.29) | (7.44) | (56.79) |
| 396.00% | (3,230.05%) | (108.63%) | (96.98%) | (750.15%) | 345.22% | 249.05% | 122.72% | |
| (301.11%) | (391.41%) | (89.35%) | (73.60%) | (245.93%) | (425.59%) | (2,365.79%) | (621.90%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
272.88% | 576.83% | (105.36%) | (56.82%) | (464.77%) | (2,721.20%) | 304.85% | 110.12% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Free Cash Flow per Share |
(227.97) | (19,920.00) | (14,490.00) | (12,846.67) | (13,695.00) | (612.05) | (38.14) | (0.77) |
Cash per Share |
23.65 | 1,606.25 | 23,734.00 | 30,073.33 | 12,245.00 | 360.26 | 1.70 | 0.14 |
Shareholders Equity per Share |
(43.21) | (10,061.25) | 20,424.00 | 28,160.00 | 6,925.00 | 68.72 | (41.36) | (1.49) |
Interest Debt per Share |
0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(43.21) | (10,061.25) | 20,424.00 | 28,160.00 | 6,925.00 | 68.72 | (41.36) | (1.49) |
Free Cash Flow |
(24.85) | (15.94) | (7.24) | (3.85) | (2.74) | (2.39) | (3.40) | (2.40) |
Working Capital |
(9.26) | (6.06) | 9.62 | 8.39 | 1.33 | 0.22 | (3.40) | (4.64) |
Capital Expenditures |
0.40 | (0.66) | — | — | — | — | — | — |
Net Current Asset Value |
(13.45) | (11.25) | 9.62 | 8.39 | 1.33 | 0.22 | (3.69) | (4.64) |
| Other line items | ||||||||
Quick Ratio |
0.22 | 0.17 | 4.58 | 6.85 | 1.60 | 1.07 | 0.14 | 0.14 |
Depreciation/Fixed assets |
— | — | — | — | 0.00 | — | — | — |
Cash ROIC |
(811.53%) | 2,795.79% | (32.81%) | (22.06%) | (69.34%) | (117.99%) | 198.71% | 258.68% |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(231.64) | (19,095.00) | (14,490.00) | (12,846.67) | (13,695.00) | (612.05) | (38.14) | (0.77) |
Capex per Share |
3.67 | (825.00) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.12 | 0.19 | 0.32 | 0.34 | 0.35 | 0.38 | 0.37 | 0.37 |
Average Payables |
6.40 | 1.75 | 0.60 | 0.58 | 0.83 | 1.13 | 1.13 | — |
Average Assets |
8.39 | 8.93 | 11.34 | 6.48 | 2.52 | 1.39 | 0.44 | 0.82 |
Average Common Equity |
(6.38) | 1.08 | 9.33 | 4.92 | 0.83 | (1.71) | (4.17) | (4.17) |
Capex to Sales |
0.00 | 0.00 | — | — | — | — | — | — |
Columns are period end dates